Monte Rosa Therapeutics Inc (GLUE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Monte Rosa Therapeutics Inc (GLUE) has a cash flow conversion efficiency ratio of -0.072x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-37.37 Million) by net assets ($521.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Monte Rosa Therapeutics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Monte Rosa Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Monte Rosa Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Monte Rosa Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Monte Rosa Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Railway Construction Corporation Limited
F:4FF
|
0.045x |
|
Galapagos N.V.
AS:GLPG
|
-0.024x |
|
Shenzhen Heungkong Holding Co Ltd
SHG:600162
|
-0.004x |
|
Realia
MC:RLIA
|
0.038x |
|
Friedrich Vorwerk Group SE
F:VH2
|
0.147x |
|
Flowers Foods Inc
NYSE:FLO
|
0.104x |
|
Three's Company Media Group Co Ltd
SHG:605168
|
-0.021x |
|
Jiangsu Jujie Microfiber Technology
SHE:300819
|
0.079x |
Annual Cash Flow Conversion Efficiency for Monte Rosa Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Monte Rosa Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Monte Rosa Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $233.06 Million | $-22.80 Million | -0.098x | -151.93% |
| 2024-12-31 | $222.94 Million | $42.00 Million | 0.188x | +177.09% |
| 2023-12-31 | $179.25 Million | $-43.80 Million | -0.244x | +28.27% |
| 2022-12-31 | $271.41 Million | $-92.47 Million | -0.341x | -99.44% |
| 2021-12-31 | $347.51 Million | $-59.36 Million | -0.171x | -136.11% |
| 2020-12-31 | $-48.73 Million | $-23.05 Million | 0.473x | -6.90% |
| 2019-12-31 | $-12.15 Million | $-6.17 Million | 0.508x | -- |
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment… Read more